MedTrace Logo

Study With M2ES and Gemcitabine for Patients With Advanced Pancreatic Cancer

NCT01218880 · Status: UNKNOWN · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 21

Last updated 2010-10-19

No results posted yet for this study

Summary

Phase I trail will be conducted to evaluate the safety of M2ES in combination with gemcitabine in locally advanced or metastatic pancreatic cancer.

Conditions

Interventions

DRUG

M2ES 7.5mg

M2ES Dosage：7.5mg/m2

DRUG

M2ES 15mg

M2ES Dosage：15mg/m2

DRUG

M2ES 30mg

M2ES Dosage：30mg/m2

DRUG

M2ES 45mg

M2ES Dosage：45mg/m2

Sponsors & Collaborators

  • Protgen Ltd

    lead INDUSTRY

Principal Investigators

  • Zhaosheng Li, MD · Shanghai Changhai Hosptial

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
60 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2010-06-30
Primary Completion
2011-07-31
Completion
2011-12-31

Countries

  • China

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01218880 on ClinicalTrials.gov